FDA
approval
· 2024-06-04
FDA Approved: VYONDYS 53 — Supplemental Application (Sarepta Therapeutics, Inc.)
Summary
The FDA approved a supplemental application for VYONDYS 53 (golodirsen) filed by Sarepta Therapeutics, expanding regulatory status for Duchenne muscular dystrop…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for VYONDYS 53 (GOLODIRSEN)